Chinese pharmaceutical firm Hualan Biological Bacterin has agreed to produce over 100 million doses of Russia's two-shot Sputnik V vaccine against COVID-19 every year, the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) said on Monday.

The fund, which markets Sputnik V globally, said the two sides are committed to the long-term partnership in terms of the vaccine production.